polymerase (PARP) inhibitors L01XK01 Olaparib L01XK02 Niraparib L01XK03 Rucaparib L01XK04 Talazoparib L01XK05 Veliparib L01XK06 Pamiparib L01XL Antineoplastic cell and gene therapy L01XL01 Sitimagene ceradenovec L01XL02 Talimogene laherparepvec L01XL03 Axicabtagene ciloleucel L01XL04 Tisagenlecleucel L01XL05 Ciltacabtagene autoleucel L01XL06 Brexucabtagene autoleucel L01XL07 Idecabtagene vicleucel L01XX Other antineoplastic agents L01XX01 Amsacrine L01XX02 Asparaginase L01XX03 Altretamine L01XX05 Hydroxycarbamide L01XX07 Lonidamine L01XX08 Pentostatin L01XX10 Masoprocol L01XX11 Estramustine L01XX16 Mitoguazone L01XX18 Tiazofurine L01XX23 Mitotane L01XX24 Pegaspargase L01XX27 Arsenic trioxide L01XX29 Denileukin diftitox L01XX33 Celecoxib L01XX35 Anagrelide L01XX36 Oblimersen L01XX40 Omacetaxine mepesuccinate L01XX41 Eribulin L01XX44 Aflibercept L01XX46 Olaparib L01XX52 Venetoclax L01XX53 Vosaroxin L01XX57 Plitidepsin L01XX58 Epacadostat L01XX59 Enasidenib L01XX62 Ivosidenib L01XX66 Selinexor L01XX67 Tagraxofusp L01XX69 Lurbinectedin L01XX72 Tazemetostat L01XX73 Sotorasib L01XX74 Belzutifan L01XX75 Tebentafusp L01XX77 Adagrasib QL01XX91 Tigilanol tiglate QL01XX92 Verdinexor L01XY Combinations of antineoplastic agents L01XY01 Cytarabine and daunorubicin L01XY02 Pertuzumab and trastuzumab L01XY03 Nivolumab and relatlimab References L01